காத்தாடி மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HepaTx appoints Salah Kivlighn as new CEO News provided by Share this article Share this article PALO ALTO, Calif., April 15, 2021 /PRNewswire/  HepaTx Corporation, a preclinical stage company developing cell therapies for the treatment of liver disease, is pleased to announce the appointment of Salah Kivlighn, PhD as Chief Executive Office. An experienced business leader, Dr. Kivlighn will succeed Co-founder Eric Schuur, PhD and assume responsibilities on April 15 th, 2021. Dr. Kivlighn brings a rare blend of science and business acumen to HepaTx. His experience spans therapeutic classes including oncology, vaccines, immuno-oncology, and cardiovascular disease treatments and multiple aspects of drug development and commercialization. His accomplishments include: guided the discovery, evolution, and commercialization of Losartan (Cozaar®), a market-leading antihypertensive drug becoming a $3.5B franchise (Merck & Co.); co-led the development and commercialization of RotaTeq

Eric schuurSalah kivlighnLosartan cozaarArthur guytonMedimmune astrazenecaStates pharmacopeiaKite pharmaceuticalsMerck coHepatx corporationUniversity of houstonChief executiveCo founder eric schuurRecently salahUnited states pharmacopeiaCommercial vice presidentChief executive officer award